PS
Therapeutic Areas
Alnylam Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AMVUTTRA (vutrisiran) | hATTR Amyloidosis with Polyneuropathy | Approved |
| ONPATTRO (patisiran) | hATTR Amyloidosis with Polyneuropathy | Approved |
| GIVLAARI (givosiran) | Acute Hepatic Porphyria (AHP) | Approved |
| OXLUMO (lumasiran) | Primary Hyperoxaluria Type 1 (PH1) | Approved |
| LEQVIO (inclisiran) | Hypercholesterolemia | Approved |
| Zilebesiran (ALN-AGT) | Hypertension | Phase 3 |
| ALN-APP | Alzheimer's Disease, Cerebral Amyloid Angiopathy | Phase 2 |
| Fitusiran (ALN-AT3SC) | Hemophilia A and B | Phase 3 |
Leadership Team at Alnylam Pharmaceuticals
YG
Yvonne Greenstreet
President & Chief Executive Officer
JV
Jeffrey V. Poulton
Chief Financial Officer
TT
Tolga Tanguler
Chief Commercial Officer
PG
Pushkal Garg
Chief Medical Officer & EVP, Therapeutics
KF
Kevin Fitzgerald
Chief Scientific Officer & SVP, Research
JM
John Maraganore
Founding CEO, Executive Chairman of the Board